Cell Therapy Next Current Issue
The following articles appeared in the print edition of Cell Therapy Next.
Table of Contents
- Driving Killer CARs into Cancer
-
- Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
- Study of LN-145 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck
- T-Lymphocytes for Prevention or Treatment of Viral Infections Following Hematopoietic Stem Cell Transplantation
- Specific Peptide-Enhanced Affinity Receptor T cells for Hepatocellular Carcinoma
- Cell Therapy Receives Orphan Drug Designation for Chronic Heart Failure
-
- FDA Approves First Gene Therapy for Spinal Muscular Atrophy in Children
- P-BCMA-101 Receives Orphan Drug Designation for Multiple Myeloma
- NCCN Releases Inaugural Pediatric ALL Clinical Practice Guidelines
- Neurotoxicity Affects Nearly Half of Patients Receiving CAR T-cell Therapy
- CAR T-Cell Therapy Total Cost can Exceed $1.5 Million per Treatment
- MD Anderson Releases Free CAR T-cell Therapy Toxicity Grading and Management App
- Outpatient CAR T-Cell Therapy Possible if Done Earlier
- Tumor-Infiltrating Lymphocytes ‘Capable of Destroying the Last Cancer Cell’
-
- New Trial Uses Bispecific CAR T-Cell Therapy to Target Pediatric ALL